Revolution Medicines has announced groundbreaking results from a Phase 3 trial for its pancreatic cancer drug, daraxonrasib. The investigational daily pill demonstrated a significant extension in patient survival and a substantial reduction in the risk of death, marking a potential paradigm shift in the treatment of this aggressive disease. In the pivotal trial, daraxonrasib nearly […]